. Efficacy and safety were assessed 21-30 days after the start of treatment. The efficacy endpoints were Investigator Cure, Clinical Cure (a composite of all 4 Amsel's criteria and Investigator Cure), Nugent Cure (Nugent score 5 4), and Therapeutic Cure (a composite of Clinical Cure and Nugent Cure). Resolution of individual Amsel's criteria was also evaluated. Treatment-emergent adverse events were monitored throughout the study.
Introduction
Bacterial vaginosis (BV) continues to be one of the most common vaginal disorders in reproductive-age women. It represents 40-50% of all cases of vaginitis, surpassing both vaginal candidiasis and vaginal trichomoniasis [1] . It causes significant patient discomfort and has been associated with many disorders of the female reproductive tract, including recurrent urinary tract infections, adnexal tenderness, postpartum endometritis, increased risk of infection after gynecologic surgery, pelvic inflammatory disease, and adverse pregnancy outcomes. BV results from replacement of the normal Lactobacillusdominant vaginal flora with polymicrobial, primarily anaerobic, bacteria. The cause of this microbial shift is not fully understood [2, 3] .
Recommended antimicrobial treatments for nonpregnant women often include oral or intravaginal therapy with clindamycin. While both oral and intravaginal administrations are effective, intravaginal medications may result in fewer of the adverse side effects associated with oral antibiotic therapy such as nausea, vomiting, and taste perversion [4, 5] . In addition, patients treated with intravaginal therapies report increased treatment satisfaction compared with those treated with oral therapies [6] . Most intravaginal therapies for BV, like oral therapies, require the inconvenience of daily use for multiple days, and this inconvenience may have a negative effect on treatment compliance and satisfaction [7] . Thus, an effective single-dose vaginal treatment for BV might be beneficial to women from a number of different points of view. [8] .
Given the ability of Clindesse TM to maintain therapeutic levels of clindamycin in the vagina for a prolonged period of time, we hypothesize that a single dose of Clindesse TM would be equivalent to a 7-day course of a conventional clindamycin phosphate intravaginal cream. Such reductions in dosing frequency have been shown to increase treatment compliance, patient satisfaction, and quality of life [7] . Thus, the purpose of the current study was to determine whether a single dose of Clindesse TM is equivalent in safety and efficacy to a 7-day regimen of Cleocin 1 vaginal cream in the treatment of BV.
Material and methods
The study was designed in accordance with the United States Food and Drug Administration FDA Center for Drug Evaluation and Research (CDER) 1998 draft guidelines for developing effective treatments for BV [2] . This was a multicenter, single (Investigator)-blind, active-controlled study. Patients were recruited at 28 clinics in the United States, each with its respective IRB/ethics board approval. All patients provided signed informed consent before any study-related procedure was performed. Eligible patients were nonpregnant women at least 18 years of age with a clinical diagnosis of BV, which was defined as meeting all of Amsel's criteria [ (on a 10-point scale). Therapeutic Cure was a composite endpoint defined as both Clinical Cure and Nugent Cure. In addition, the 4 Amsel's criteria were each evaluated individually. The TOC visit was selected to demonstrate both status and duration of outcome. The per-protocol (PP) population was selected for the efficacy analyses in accordance with demonstration of equivalence between treatments.
The safety of the 2 treatments was evaluated by monitoring treatment-emergent adverse events (AEs) throughout the study.
Statistical methods
Efficacy endpoints were analyzed using the centerstratified Cochran-Mantel-Haenszel (CMH) estimate of the difference in cure rates and corresponding confidence interval [11] . Clindesse TM was to be considered equivalent to Cleocin 1 if the 2-sided 95% confidence interval (CI) for the difference in cure rates (Clindesse TM minus Cleocin 1 ) had a lower limit greater than 7 20% and an upper limit less than + 20%. Efficacy analyses were performed using a PP population, which included patients who administered study medication, had baseline Nugent scores 5 4, had assessment results at the TOC visit or discontinued participation in the study prior to the TOC visit due to lack of efficacy, had no antimicrobial therapy for conditions other than BV during the study, started study medication within 48 hours of the entry visit, and had no major violations of the study protocol. All patients who administered at least 1 dose of study medication were included in the safety analyses.
Results
Of the 540 patients enrolled in the study ( tients (P = 0.792). There were no statistically significant differences in cure rates between treatment groups and the 95% CIs for the differences were consistent with equivalence in the alleviation of BV signs using both 2 and 3 of the 4 Amsel's criteria. In addition, there were no statistically significant differences in resolution of Amsel's criteria between the treatment groups when the criteria for clue cells ( 5 20%) and a negative ''whiff'' test were evaluated together (P = 0.965) or when the criteria for clue cells, ''whiff'' test, and vaginal pH ( 5 4.7) were evaluated together (P = 0.539). The cure rates associated with each Amsel's criterion and selected groups of criteria are presented in Table III . Table I . Primary reasons for non-evaluability in the per-protocol population by treatment group. AEs and study medication-related AEs were not statistically different between the 2 treatment groups (P = 0.386 for overall AEs and P = 0.336 for study medication-related AEs). Overall, among the 528 patients who received study medication, 5 (0.9%) were discontinued from the study due to AEs. Three (1.1%) Clindesse TM -treated patients were discontinued due to Vaginal Yeast Infection, Candidiasis, and Allergic Reaction to Study Drug (1 patient each). Two patients (0.8%) in the Cleocin 1 group were discontinued due to Vaginal Yeast Infections. There was 1 serious AE (cellulitis) reported by a patient receiving Cleocin 1 during the study. The event was judged to be unrelated to the study medication by the investigator.
Discussion
As we hypothesized, analyses of interpretive, symptomatic, and diagnostic efficacy variables revealed no statistically significant differences between use of clindamycin phosphate 2%, administered in a singledose vaginal cream (Clindesse TM ), and in a standard 7-day vaginal cream (Cleocin 1 ).
Investigator Cure is an interpretive measure representing the requirement for additional therapy Table II . Efficacy outcomes at the Test-of-Cure Visit (number and % of evaluable patients cured). N) and to have achieved cure if data for 1 Amsel's criterion were missing, but all other criteria were consistent with cure. Although there may be some differences between these studies (e.g., study populations, inclusion criteria, patient evaluability), the cure rates observed were comparable to the 87.5% and 83.2% rates observed using the same definition of cure with Clindesse TM and Cleocin 1 , respectively, in this study. Previous clinical studies performed with Cleocin 1 defined BV cure as resolution of 2 of Amsel's criteria (the ''whiff'' test and clue cell criteria) and reported a cure rate of 86% for a 7-day dosing regimen [12] . This is comparable to the 84.4% and 84.0% cure rates observed using these 2 criteria with Clindesse TM and Cleocin 1 , respectively, in this study.
In the study reported here, there were no significant differences in the incidence of AEs between the treatment groups, and AEs commonly associated with oral therapy (e.g., nausea, taste perversion) were reported in less than 1% of the patients in either treatment group.
Conclusions
Overall, a single-dose regimen of Clindesse TM was shown to be comparable with respect to both efficacy and safety to Cleocin 1 . Clindesse TM , however, provides equivalent efficacy and safety in a single dose, compared with a 7-dose regimen of Cleocin 1 .
It has been shown that reducing dose frequency increases the patient's compliance with treatment, symptom control, satisfaction with treatment, and quality of life in a number of disease states [7] . Clindesse TM offers these advantages, and therefore represents an important therapeutic advance in the treatment of BV. § N Denotes the number of patients with non-missing data in the PP population for each treatment group. n and % denote the frequency of patients cured in the PP population within each endpoint for each treatment group; | P-value was derived using FET to determine if rates of events differed between treatment groups.
